Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2015
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
gptkb:G02CX02
|
| gptkbp:brand |
gptkb:Addyi
|
| gptkbp:CASNumber |
167933-07-5
|
| gptkbp:chemicalFormula |
C20H21F3N4O
|
| gptkbp:contraindication |
alcohol use
liver impairment |
| gptkbp:firstBook |
yes
|
| gptkbp:genericName |
gptkb:flibanserin
|
| https://www.w3.org/2000/01/rdf-schema#label |
Addyi
|
| gptkbp:indication |
pre-menopausal women
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Sprout_Pharmaceuticals
|
| gptkbp:marketedIn |
gptkb:United_States
|
| gptkbp:mechanismOfAction |
serotonin receptor modulator
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:prescriptionStatus |
Rx-only
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
dizziness fatigue somnolence |
| gptkbp:usedFor |
gptkb:hypoactive_sexual_desire_disorder
|
| gptkbp:bfsParent |
gptkb:Valeant_Pharmaceuticals
|
| gptkbp:bfsLayer |
6
|